Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telaprevir

Next Previous
X
Search
Drug Profile

Telaprevir

Alternative Names: Incivek; Incivo; LY-570310; MP-424; Telavic; VX-950

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company; Vertex Pharmaceuticals
  • Developer Janssen R&D Ireland; Mitsubishi Tanabe Pharma Corporation; Vertex Pharmaceuticals
  • Class Antivirals; Cyclohexanes; Cyclopentanes; Cyclopropanes; Peptidomimetics; Pyrazines; Pyrrolidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 01 Aug 2017 Discontinued - Phase-I/II for Hepatitis C (Combination therapy, In adolescents, In children) in USA, Italy, Spain, Belgium, Germany and United Kingdom (PO), because not listed on Vertex and Janssen Pharmaceutica pipeline, August 2017
  • 07 Jun 2016 Vertex terminates a phase I/II trial in Hepatitis C (Combination therapy, In adolescents, In children) in USA, United Kingdom, Belgium, Germany, Italy and Spain (NCT01701063)
  • 11 May 2016 Mitsubishi Tanabe Pharma Corporation terminates its co-development agreement with Toray for Telaprevir in Japan (Mitsubishi Tanabe Pharma Corporation, May 2016)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top